Uncategorized-EN
National patient groups around the world say “We are #HereForYou”
COVID-19 and the fact that you as cancer patients and survivors are considered a “risk group” causes a lot of uncertainties: A lot of you feel left alone with your fears and questions. However, many of our national patient advocacy groups for sarcoma, GIST and desmoid patients keep on providing support and information to you…
Read MoreStudy the correlation between desmoid tumors and pregnancy
In collaboration with the Fondazione IRCCS Istituto Nazionale dei Tumori, the Desmoid Foundation Italy is launching a survey to study the correlation between desmoid tumors and pregnancy. The results of this study will help to understand how desmoid tumors behave DURING pregnancy with the aim of improving the future of our patients who dream of…
Read MoreSarcoma Expert new EORTC President-Elect
Professor Winette van der Graaf, The Netherlands, has been elected as new EORTC President-Elect from 2021-2024 – our heartfelt congratulations to a dedicated and enthusiastic #sarcoma expert! Read more: https://bit.ly/2TQC8o7
Read MoreTreatment News
European Commission Grants Lilly’s olaratumab (LARTRUVOTM), in Combination with Doxorubicin, Approval for the Treatment of Advanced Soft Tissue Sarcoma in Europe Olaratumab, in combination with doxorubicin, is the first front-line therapy approved in four decades for advanced soft tissue sarcoma in Europe JGDG study showed olaratumab, in combination with doxorubicin, offered a median 11.8-month increase…
Read MoreStudy Results
The following table lists the results of some of the many clinical trials available worldwide for sarcoma, GIST or desmoid patients. For more information about some of the ongoing trials, click here. No Trial Name Agents Phase Status Results Sponsor 1 Study 62005 Imatinib in twodifferent dosings III Closed Results Study 62005 EORTC Note: The…
Read MoreResults Study 62005
Ten-year progression-free and overall survival in patients with unresectable or metastatic gastrointestinal stromal tumours (GIST). Long-term analysis of the EORTC, ISG, AGITG intergroup Phase III randomized trial on imatinib at two dose levels. HOW MANY patients participated? A total of 946 patients at 56 centers in 13 countries in Europe and Australia/New Zealand/Singapore took part…
Read MoreEarly Involvement
Clinical studies are an essential step in the development of novel treatment methods for cancer and other diseases. They show researchers what works for the welfare of patients and what does not. In addition to safety and effectiveness they also determine whether the side effects of a new treatment are acceptable and, increasingly, what quality…
Read MorePatients & Studies
Research Networks
The EORTC Soft Tissue and Bone Sarcoma Group (STBSG) The objectives of the STBSG were to develop, stimulate and co-ordinate studies on all aspects of the treatment of soft tissue sarcomas (STS) as well as to organise congresses, symposia and conferences to promote these studies. Today the STBSG has members from 56 institutions from 14…
Read MoreSubmitted Abstracts
Setting the international research agenda for sarcoma together with patients and carers: first results of the Sarcoma Patient EuroNet (SPAEN) priority setting partnershipPublished in ESMO Open, June 2022 Research in sarcomas has historically been the domain of scientists and clinicians attempting to understand the disease to develop effective treatments. This traditional approach of placing scientific…
Read More